Astellas buys into Frequency's regenerative med strategy with a $625M alliance on hearing loss
The executive team at Frequency Therapeutics never oversold the results of their maiden Phase I/II study for a new drug to rectify hearing loss. It was, they said back in April, primarily about safety and tolerability, where their drug FX-322 performed as they had hoped.
That early glimpse of efficacy everyone searches for in their first try on humans?
(I)mprovements in hearing function, including audiometry and word scores, were observed in multiple FX-322 treated patients.
We don’t know exactly what that means. But whatever the details, Astellas found enough in the data to jump in with a sizable collaboration deal.
Basic subscription required
Unlock this story instantly and join 57,900+ biopharma pros reading Endpoints daily — and it's free.